ClinicalTrials.gg
CompletedNCT05865886Updated Jun 23, 2026Results posted

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

A Phase 2 interventional study of BI 1291583 and Placebo to BI 1291583 in Cystic Fibrosis and Bronchiectasis, sponsored by Boehringer Ingelheim. Completed at 24 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Cystic Fibrosis by Boehringer Ingelheim — none open to participants now, 1 under way, none of them phase 3. Cystic Fibrosis · Boehringer Ingelheim.

Enrollment
9th of 11
22 · median 52
Started
2024
with 1 other
Phase 2
4 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Cystic Fibrosis by Boehringer Ingelheim, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 4 in phase 2, and was the 9th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 11 studies in Cystic Fibrosis by Boehringer Ingelheim is open now. The open studies under Cystic Fibrosis, anywhere →

Who these studies take

Of the 155 Cystic Fibrosis studies recruiting now, 94 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Cystic Fibrosis by Boehringer Ingelheim as a file.
02

Study summary

This study is open to adults aged 18 years and older with cystic fibrosis bronchiectasis.

The purpose of this study is to find out whether a medicine called BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis. Participants are put randomly into 2 groups. One group takes BI 1291583 tablets and the other group takes placebo tablets. Placebo tablets look like BI 1291583 tablets but do not contain any medicine. Participants in both groups take 1 tablet once a day for 12 weeks. Participants have twice the chance of being placed in the BI 1291583 group than in the placebo group.

Participants are in the study for about 6 months. During this time, they visit the study site 7 times. At the visits, the doctors check the health of the participants and note any health problems that could have been caused by BI 1291583.

03

Conditions studied

  • Cystic Fibrosis
  • Bronchiectasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of patients when signing the ≥18 years
  2. Historical clinical diagnosis of Cystic fibrosis (CF) (symptoms of CF and sweat chloride ≥ 60 mmol/L and/or 2 CF-causing Cystic fibrosis transmembrane conductance regulator (CFTR) mutations)
  3. Investigator-confirmed diagnosis of Bronchiectasis (BE) by Computed tomography (CT) scan and clinical history consistent with BE (e.g., cough, chronic sputum production, recurrent respiratory infections). Subjects whose past chest CT records are not available will undergo a chest CT scan during Screening. Historical scans must not be older than 5 years
  4. History of pulmonary exacerbations requiring antibiotic treatment. In the 12 months before Visit 1, patients must have had either:

    1. at least 2 exacerbations, or
    2. at least 1 exacerbation and an St. George's Respiratory Questionnaire (SGRQ) Symptoms score of >40 at screening visit 1 For patients on stable oral or inhaled antibiotics as chronic treatment for BE, at least one exacerbation must have occurred while on stable antibiotics.
  5. Patients must be able to provide spontaneous or induced sputum samples. Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  1. Moderate or severe liver disease (defined by score B or C hepatic impairment) or (AST) and/or Alanine aminotransferase (ALT) > 3.0x (ULN) at Visit 1
  2. Estimated (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \< 30 mL/min at Visit 1
  3. Absolute blood \< 1,000/mm\^3 (equivalent to \< 1000 cells/μL or \< 10\^9 cells/L) at Visit 1
  4. Any findings in the medical examination (including blood pressure (BP), pulse rate (PR), or (ECG)) and/or laboratory value assessed at Visit 1 or during screening period that in the opinion of the investigator may put the patient at risk by participating in the trial
  5. Positive serological tests for , (also confirmed with Hepatitis C virus ribonucleic acid (HCV RNA)), or (HIV) infection, or known infection status.

Further exclusion criteria apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    5 mg BI 1291583

    Drug: BI 1291583

  • Placebo comparator
    Placebo

    Drug: Placebo to BI 1291583

Interventions

  • Once daily oral administration of 5 milligram (mg) tablets of BI 1291583 for 12 weeks.

    Also known as: Verducatib

  • DrugPlacebo to BI 1291583

    Once daily oral administration of tablets of placebo matching BI 1291583 for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Occurrence of Any Treatment Emergent Adverse Events

    Occurrence of any treatment emergent adverse events is expressed as percentages of participants with treatment emergent adverse events. Percentages are rounded to one decimal place.

    Time frame: From first dose of trial drug administration until last dose of trial drug administration plus 28 days of residual effect period, up to 16 weeks.

Secondary outcomes

  1. Relative Change From Baseline in NE Activity, in Sputum, at Week 8 After First Drug Administration

    Relative change from baseline in neutrophil elastase (NE) activity, in sputum, at Week 8 after first drug administration is reported. Relative change from baseline at Week 8 in neutrophil elastase was calculated as below: Relative fluorescence unit (RFU) at Week 8-Relative fluorescence unit at baseline)\*100%/Relative fluorescence unit at baseline.

    Time frame: Before the first drug administration (baseline: mean value of screening and Week 0 prior to the first treatment intake) and Week 8 after first study drug administration.

  2. Area Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h After the First Dose (AUC0-6)

    Area under the curve of BI 1291583 in plasma over a uniform dosing interval tau=6h after the first dose (AUC0-6) is reported.

    Time frame: Before drug administration and 1 hour (h), 3.5h, 6h after administration of the first dose of BI 1291583 at Day 1.

  3. Area Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h at Steady State (AUC0-6,ss)

    Area under the curve of BI 1291583 in plasma over a uniform dosing interval tau=6h at steady state (AUC0-6,ss) is reported.

    Time frame: Before drug administration at Day 85 and 1 hour (h), 3.5h, 6h after administration of BI 1291583 at Day 85.

  4. Maximum Measured Concentration of BI 1291583 in Plasma After the First Dose

    Maximum measured concentration of BI 1291583 in plasma after the first dose is reported.

    Time frame: Before drug administration and 1 hour (h), 3.5h, 6h, and 8h after administration of the first dose of BI 1291583 at Day 1.

  5. Maximum Measured Concentration of BI 1291583 in Plasma at Steady State

    Maximum measured concentration of BI 1291583 in plasma at steady state is reported.

    Time frame: Before drug administration at Day 85 and 1 hour (h), 3.5h, 6h after administration of BI 1291583 at Day 85.

07

Results

Posted Nov 18, 2025

Participant flow

This was a randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (Clairafly™).

Participant flow — Overall Study
MilestonePlacebo5 mg BI 1291583
Started715
Completed714
Not completed01
Withdrew: Serious adverse event01

Outcome measures

PrimaryOccurrence of Any Treatment Emergent Adverse Events

Occurrence of any treatment emergent adverse events is expressed as percentages of participants with treatment emergent adverse events. Percentages are rounded to one decimal place.

Time frame:
From first dose of trial drug administration until last dose of trial drug administration plus 28 days of residual effect period, up to 16 weeks.
Reported as:
Number · Percentage of participants
Occurrence of Any Treatment Emergent Adverse Events
Percentage of participantsPlaceboBI 1291583 5 mg
Occurrence of Any Treatment Emergent Adverse Events85.793.3
SecondaryRelative Change From Baseline in NE Activity, in Sputum, at Week 8 After First Drug Administration

Relative change from baseline in neutrophil elastase (NE) activity, in sputum, at Week 8 after first drug administration is reported. Relative change from baseline at Week 8 in neutrophil elastase was calculated as below: Relative fluorescence unit (RFU) at Week 8-Relative fluorescence unit at baseline)\*100%/Relative fluorescence unit at baseline.

Time frame:
Before the first drug administration (baseline: mean value of screening and Week 0 prior to the first treatment intake) and Week 8 after first study drug administration.
Reported as:
Mean · percent change in RFU
Relative Change From Baseline in NE Activity, in Sputum, at Week 8 After First Drug Administration
percent change in RFUPlacebo5 mg BI 1291583
Relative Change From Baseline in NE Activity, in Sputum, at Week 8 After First Drug Administration39.69 ± 134.67-65.95 ± 49.37
SecondaryArea Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h After the First Dose (AUC0-6)

Area under the curve of BI 1291583 in plasma over a uniform dosing interval tau=6h after the first dose (AUC0-6) is reported.

Time frame:
Before drug administration and 1 hour (h), 3.5h, 6h after administration of the first dose of BI 1291583 at Day 1.
Reported as:
Geometric mean · hours *nanomole/Liter (h*nmol/L)
Area Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h After the First Dose (AUC0-6)
hours *nanomole/Liter (h*nmol/L)5 mg BI 1291583
Area Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h After the First Dose (AUC0-6)14.0 ± 65.3
SecondaryArea Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h at Steady State (AUC0-6,ss)

Area under the curve of BI 1291583 in plasma over a uniform dosing interval tau=6h at steady state (AUC0-6,ss) is reported.

Time frame:
Before drug administration at Day 85 and 1 hour (h), 3.5h, 6h after administration of BI 1291583 at Day 85.
Reported as:
Geometric mean · hours *nanomole/Liter (h*nmol/L)
Area Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h at Steady State (AUC0-6,ss)
hours *nanomole/Liter (h*nmol/L)5 mg BI 1291583
Area Under the Curve of BI 1291583 in Plasma Over a Uniform Dosing Interval Tau=6h at Steady State (AUC0-6,ss)65.9 ± 64.5
SecondaryMaximum Measured Concentration of BI 1291583 in Plasma After the First Dose

Maximum measured concentration of BI 1291583 in plasma after the first dose is reported.

Time frame:
Before drug administration and 1 hour (h), 3.5h, 6h, and 8h after administration of the first dose of BI 1291583 at Day 1.
Reported as:
Geometric mean · nmol/L
Maximum Measured Concentration of BI 1291583 in Plasma After the First Dose
nmol/L5 mg BI 1291583
Maximum Measured Concentration of BI 1291583 in Plasma After the First Dose3.33 ± 74.4
SecondaryMaximum Measured Concentration of BI 1291583 in Plasma at Steady State

Maximum measured concentration of BI 1291583 in plasma at steady state is reported.

Time frame:
Before drug administration at Day 85 and 1 hour (h), 3.5h, 6h after administration of BI 1291583 at Day 85.
Reported as:
Geometric mean · nmol/L
Maximum Measured Concentration of BI 1291583 in Plasma at Steady State
nmol/L5 mg BI 1291583
Maximum Measured Concentration of BI 1291583 in Plasma at Steady State11.6 ± 69.9

Adverse events

Collected over All-Cause Mortality, Serious Adverse Events and other adverse events: From first dose of trial drug administration until last dose of trial drug administration plus 28 days of residual effect period, up to 16 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/7 (0%)1/7 (14.3%)6/7 (85.7%)
5 mg BI 12915830/15 (0%)5/15 (33.3%)13/15 (86.7%)
Most frequent serious events
Most frequent serious events
EventPlacebo5 mg BI 1291583
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/73/15
Infective exacerbation of bronchiectasisInfections and infestations1/71/15
Hepatic cirrhosisHepatobiliary disorders0/71/15
SeizureNervous system disorders0/71/15
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPlacebo5 mg BI 1291583
DiarrhoeaGastrointestinal disorders2/70/15
AsthmaRespiratory, thoracic and mediastinal disorders2/70/15
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations1/74/15
AnaemiaBlood and lymphatic system disorders1/70/15
Conjunctivitis allergicEye disorders1/70/15
EnteritisGastrointestinal disorders1/70/15
Otitis externaInfections and infestations1/70/15
PneumoniaInfections and infestations1/70/15
Pneumonia viralInfections and infestations1/70/15
HeadacheNervous system disorders1/72/15

Baseline characteristics

Treated Set (TS): included all randomised patients who were documented to have taken at least one dose of investigational treatment.

Age, Continuous
Age, Continuous(years)Placebo5 mg BI 1291583Total
Mean32.4 ± 9.432.3 ± 11.032.4 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo5 mg BI 1291583Total
Female459
Male31013
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo5 mg BI 1291583Total
Hispanic or Latino011
Not Hispanic or Latino71421
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo5 mg BI 1291583Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White71522
More than one race000
Unknown or Not Reported000
08

Study locations

24 sites
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Central Florida Pulmonary Group
    Altamonte Springs, Florida 32701, United States
  • Chest Medicine Associates
    South Portland, Maine 04106, United States
  • Northwell Health Physician Partners
    New York, New York 10028, United States
  • Columbia University Medical Center-New York Presbyterian Hospital
    New York, New York 10032, United States
  • Oregon Health and Sciences University
    Portland, Oregon 97239, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Brussels - UNIV UZ Brussel
    Brussels, 1090, Belgium
  • HOP Arnaud de Villeneuve
    Montpellier, 34295, France
  • Hôpital Cochin
    Paris, 75679, France
  • Hôpital Charles Nicolle
    Rouen, 76031, France
  • Charité - Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
    Essen, 45239, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Klinikum der Universität München AÖR
    München, 80336, Germany
  • Azienda Ospedaliera Meyer
    Florence, 50139, Italy
  • Istituto G. Gaslini
    Genova, 16147, Italy
  • IRCCS Fondazione Ospedale Maggiore
    Milan, 20122, Italy
  • AOU San Luigi Gonzaga
    Orbassano (TO), 10043, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona
    Verona, 37126, Italy
  • Amsterdam UMC, location VUMC
    Amsterdam, 1081 HV, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28049, Spain
09

References and documents

Publications

  • Badorrek P, Diefenbach C, Kogler H, Eleftheraki A, Seitz F, Hohlfeld JM. Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers. Clin Transl Sci. 2024 Aug;17(8):e13891. doi: 10.1111/cts.13891. PubMed 39175217 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Oct 2024, 6 months.

Results were first posted in Nov 2025, 1 year 1 month after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 6 months is below that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2023
First posted
May 19, 2023
StartActual
Apr 5, 2024
Primary completionActual
Oct 7, 2024
CompletionActual
Oct 7, 2024
Results first posted
Nov 18, 2025
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05865886
Responsible party
Sponsor
First posted
May 19, 2023
Start date
Apr 5, 2024
Primary completion
Oct 7, 2024
Completion
Oct 7, 2024
Results posted
Nov 18, 2025
Last update
Jun 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verducatib

Start the discussion